Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 28, 2023 - Issue 3
Submit an article Journal homepage
5,823
Views
0
CrossRef citations to date
0
Altmetric
Editorial

What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II

Giuseppe D’Angeloa Department of Public Health, University of Naples Federico II, Naples, ItalyView further author information
,
Mario Ascionea Department of Public Health, University of Naples Federico II, Naples, ItalyORCID Iconhttps://orcid.org/0000-0002-7845-1149View further author information
ORCID Icon,
Ilaria Morraa Department of Public Health, University of Naples Federico II, Naples, ItalyView further author information
,
Paolo Verrazzob Hospital Santa Maria delle Grazie of Pozzuoli - ASL Napoli 2 Nord, Naples, ItalyView further author information
,
Giuseppe Bifulcoa Department of Public Health, University of Naples Federico II, Naples, ItalyView further author information
,
Pierluigi Giampaolinoa Department of Public Health, University of Naples Federico II, Naples, ItalyView further author information
&
Luigi Della Cortec Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, ItalyCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-0584-2181View further author information
ORCID Icon show all
Pages 149-152 | Published online: 22 Sep 2023

References

  • Azziz R, Woods, KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004:89;2745–2749. doi: 10.1210/jc.2003-032046
  • Sadeghi HM, Adeli I, Calina D, et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022 Jan 6;23(2):583. doi: 10.3390/ijms23020583
  • Snabes MC, Ng J, Li H, et al. Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome. F S Rep. 2023 Feb21;4(2):206–212. doi: 10.1016/j.xfre.2023.02.007
  • Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377:28–40. doi: 10.1056/NEJMoa1700089
  • Surrey E, Taylor HS, Giudice L, et al. Long- term outcomes of elagolix in women with endometriosis: results from 2 extension studies. Obstet Gynecol. 2018;132:147–160. doi: 10.1097/AOG.0000000000002675
  • Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382:328–340. doi: 10.1056/NEJMoa1904351
  • Ruddenklau A, Campbell RE. Neuroendocrine impairments of polycystic ovary syndrome. Endocrinology. 2019 Oct 1;160(10):2230–2242. doi: 10.1210/en.2019-00428
  • Lippincott MF, León S, Chan Y-M, et al. Hypothalamic reproductive endocrine pulse generator activity independent of neurokinin B and dynorphin signaling. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4304–4318. doi: 10.1210/jc.2019-00146
  • Blank SK, McCartney CR, Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update. 2006 Jul;12(4):351–361. doi: 10.1093/humupd/dml017
  • Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20:485–500. doi: 10.1093/humupd/dmu009
  • Skorupskaite K, George JT, Veldhuis JD, et al. Interactions between neurokinin B and kisspeptin in mediating estrogen feedback in healthy women. J Clin Endocrinol Metab. 2016 Dec;101(12):4628–4636. doi: 10.1210/jc.2016-2132
  • Fraser GL, Obermayer-Pietsch B, Laven J, et al. Randomized Controlled trial of neurokinin 3 receptor antagonist Fezolinetant for treatment of polycystic ovary syndrome. J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3519–e3532. doi: 10.1210/clinem/dgab320
  • Sam S, Ehrmann DA. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017;60(9):1656–1661. doi: 10.1007/s00125-017-4306-3
  • Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.Diabetologia. 2018;61(10):2098–2107. doi: 10.1007/s00125-018-4669-0
  • Tan S, Ignatenko S, Wagner F, et al. Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double-blind, phase 2 trial. Diab Obes Metab. 2021;23(11):2595–2599. doi: 10.1111/dom.14495

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.